Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 7/20 | 0.83 |
| ▸ | CDK4 | P11802 | 11/20 | 0.80 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.80 |
| ▸ | CCND1 | P24385 | 11/20 | 0.80 |
| ▸ | CDK2 | P24941 | 11/20 | 0.80 |
| ▸ | CCND3 | P30281 | 11/20 | 0.80 |
| ▸ | JAK2 | O60674 | 6/20 | 0.80 |
| ▸ | JAK1 | P23458 | 6/20 | 0.80 |
| ▸ | TYK2 | P29597 | 6/20 | 0.80 |
| ▸ | JAK3 | P52333 | 6/20 | 0.80 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.69 |
| ▸ | FLT1 | P17948 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 5/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3532060 | 0.92 | CHEK1 (0.79) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5251709 | 0.91 | CHEK1 (1.00) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5508118 | 0.89 | PDPK1 (0.74) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5246946 | 0.89 | CDK4 (1.00) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5953064 | 0.86 | FGFR1 (0.69) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5250638 | 0.86 | CDK4 (0.71) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL311148 | 0.82 | FGFR1 (1.00) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL29714859 | 0.82 | FGFR1 (1.00) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL3537487 | 0.82 | ITK (0.80) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL3543632 | 0.82 | FGFR1 (0.71) | CHEK1CDK4CCNA2CCND1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015075051-A1 | ALLOSTERIC INHIBITORS OF ATYPICAL PROTEIN KINASES C | UNIVERSITAET DES SAARLANDES (DE) | 2015-05-28 | — | — | WO | disclosed |
| US-20120270313-A1 | Compositions and Methods for Establishing and Maintaining Stem Cells in an Undiffferentiated State | UNIVERSITY OF KANSAS (US) | 2012-10-25 | — | — | US | disclosed |
| US-8193235-B2 | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state | UNIVERSITY OF KANSAS (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100317100-A1 | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state | UNIVERSITY OF KANSAS | 2010-12-16 | — | — | US | disclosed |
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317100-A1 | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state | MCL1, PRKCA, PRKCI | CHEK1 661/4885CDK4 259/4885CCNA2 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.